Nurix Enrolls First Patient in Phase 1b/2 Bexobrutideg Combination Study
Nurix Therapeutics has dosed the first patient in the Phase 1b/2 trial NX-5948-203, evaluating the investigational BTK degrader bexobrutideg combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic lymphoma. Conducted under Nurix’s global collaboration with Roche, the study assesses the therapy's safety, tolerability, and clinical activity. Results will guide future registrational strategies, including potential combinations with anti-CD20 antibodies across various treatment lines and expansion into other B-cell malignancies, representing a key developmental milestone for the pipeline.
Nurix Therapeutics, Inc. announced the enrollment of the first patient in NX-5948-203, a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Bexobrutideg is an investigational oral Bruton’s tyrosine kinase (BTK) degrader. Venetoclax, a BCL2 inhibitor, is described as a standard-of-care therapy for patients with CLL/SLL. The study is designed to assess the safety, tolerability and clinical activity of the combination.
NX-5948-203 is being conducted under the global collaboration between Nurix and Roche. Data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL.
Those strategies include evaluating bexobrutideg with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts of patients with relapsed or refractory and previously untreated CLL. The trial data may also support potential expansion into other B-cell malignancies.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.